All In Biotech

Drug Trial Radar · NCT06716905

Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Dose Escalations of ACT500 (Formerly Known as NM6606) in Chinese Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Mar 6, 2025

Primary completion

Sep 22, 2025

Study completion Sep 22, 2025

Sponsor

Sponsor type
Industry
Collaborators
Zhongnan Hospital
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a multiple-dose escalation study (Part2,MAD study phase). It's aimed to evaluate the safety, tolerability, and pharmacokinetics (PK) of ACT500 in healthy adult participants, and to explore possible metabolites and biomarkers of ACT500.

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

  • ACT500 tabletsDrug

    Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1

  • PlaceboDrug

    Participants will receive placebo matched to ACT500 Tablets.

  • ACT500 tabletsDrug

    Participants will receive multiple ascending oral dose of ACT500 Tablets under fasting state once daily for 7 days in Part 2.

  • PlaceboDrug

    Participants will receive placebo matched to ACT500 Tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event(AE)Time frame: SAD:Day1-8; MAD:Day1-22.
  2. Serious Adverse EventTime frame: SAD:Day1-8; MAD:Day1-22.
  3. body temperatureTime frame: SAD:Day1-5; MAD:Day1,Day7-22.
  4. respirationTime frame: SAD:Day1-5; MAD:Day1,Day7-22.
  5. pulseTime frame: SAD:Day1-5; MAD:Day1,Day7-22.
  6. heart rateTime frame: SAD:Day1-5; MAD:Day1,Day7-22.
  7. blood pressureTime frame: SAD:Day1-5; MAD:Day1,Day7-22.
  8. Physical ExaminationTime frame: SAD:Day1,Day3-8; MAD:Day1,Day3-22.
  9. Number of Participants with 12-Lead Electrocardiogram FindingsTime frame: SAD:Day-1,Day5 ; MAD:Day-1,Day3,Day8and D14.
  10. Number of Participants with Dynamic electrocardiogram(ECG)FindingsTime frame: SAD:Day1; MAD:Day1,Day7.
  11. Number of Participants with Abnormal Laboratory Parameters FindingsTime frame: SAD:Day1-8; MAD:Day1-22.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.